2018³â Á¦ 13Â÷ ´ëÇѹé½ÅÇÐȸ Ãß°èÇмú´ëȸ : 2018-09-28
±³À°ÀÏÀÚ : 2018-09-28
±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ
±³À°ÁÖÁ¦ :
2018³â Á¦ 13Â÷ ´ëÇѹé½ÅÇÐȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇѹé½ÅÇÐȸ(ÀÎ)
´ã´çÀÚ : ÀÌ¿µ¼ö
¿¬¶ôó : 02-2258-7472
À̸ÞÀÏ :
office@korvac.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, À̺ñÀÎÈÄ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í ȸ¿ø »çÀüµî·Ï µî±Þº° 3¸¸¿ø, 5¸¸¿ø, ºñȸ¿ø »çÀüµî·Ï 8¸¸¿ø ȸ¿ø ÇöÀåµî·Ï µî±Þº° 5¸¸¿ø, 7¸¸¿ø, ºñȸ¿ø ÇöÀåµî·Ï 10¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 08:30~09:00 Opening °ÁøÇÑ(°¡Å縯´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 09:00~09:20 MiRNA-150-mediated Foxo1 Regulation Programs CD8+ T cell Differentiation ÇÏ»óÁØ(¿¬¼¼´ë »ýÈÇаú)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 09:20~09:40 Modulation of T cell immunity using cell-penetrating peptide for treating inflammatory diseases, cancer and vaccine development ÃÖÁ¦¹Î(ÇѾç´ë)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 09:40~10:00 NOX2-mediated ROS Generation in Macrophages via Endocytosis of Monomeric TLR4-MD2 Complex in Non-Alcoholic Fatty Liver Disease Á¤¿øÀÏ(KAIST)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 10:00~10:20 Cancer Immunotherapy with Engineered Salmonella typhimurium secreting Heterologous Flagellin ÀÌÁØÇà(Àü³²´ë ¹Ì»ý¹°Çб³½Ç)
ÈÞ½Ä 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 10:20~10:40 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 10:40~11:00 The Korean Influenza National Immunization Program: Overview Á¤ÈñÁø(°í·Á´ë °¨¿°³»°ú)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 11:00~11:20 From Vaccine Import to Self-Reliance: Looking Back on the Development ÃÖ´öÈ£(Çѱ¹¹é½Å)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 11:20~11:40 Pandemic Preparedness ¹®»óÁØ(Áúº´°ü¸®º»ºÎ)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 11:40~12:20 A New Paradigm for Immunologists: The Protein-Homeostasis-System Hypothesis ÀÌ°æÀÏ(°¡Å縯ÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±âŸ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 12:20~12:50 ´ëÇѹé½ÅÇÐȸ ÃÑȸ ()
½Ä»ç 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 12:50~13:40 Á¡½É½Ä»ç ()
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 13:40~14:00 Updated Approval Regulation about Vaccine: Focus on Risk Management Plan and Information for Experts ±èµµ±Ù(½ÄÇ°ÀǾàÇ°¾ÈÀüó)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 14:00~14:20 Evaluation of Quadrivalent Influenza Vaccine Clinical Trials °ûº´¿Á(½ÄÇ°ÀǾàÇ°¾ÈÀüó)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 14:20~14:40 Vaccine against Mycoplasma ÀÌ»ó¿ø(°Ç±¹´ë ¼öÀÇÇаú)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 14:40~15:00 Foot and Mouth Disease Vaccine ÀÌÁ¾¼ö(Ãæ³²´ë ¼öÀǹ̻ý¹°Çб³½Ç)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 15:00~15:20 PCV2 vaccine äÂùÈñ(¼¿ï´ë ¼öÀÇÇаú)
ÈÞ½Ä 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 15:20~15:40 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 15:40~16:00 Staphylococcus aureus Vaccine ±è¾ç¼ö(¿ï»ê´ë °¨¿°³»°ú)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 16:00~16:20 Clostridium difficile Vaccine ±èÁöÀº(ÇѾç´ë °¨¿°³»°ú)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 16:20~16:40 HIV/AIDS Vaccine ½Å¼Ò¿¬(°¡Å縯°üµ¿´ë °¨¿°³»°ú)
±³À°½Ã°£ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 16:40~17:30 Poster Presentation Session À̵¿°Ç(°¡Å縯´ë °¨¿°³»°ú)
±âŸ 09¿ù 28ÀÏ °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü 1Ãþ ¸¶¸®¾ÆȦ 17:30~17:40 Closing ±è¿ìÁÖ(°í·Á´ë °¨¿°³»°ú)